Healthcare Online Network
SEE OTHER BRANDS

Your top news on healthcare and wellness

Press Releases

Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Healthcare Online Network.

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for...

Apyx Medical Corporation Announces Launch of Renuvion® in China

Apyx Medical Corporation Announces Launch of Renuvion® in China

Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance CLEARWATER, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Apyx...

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial 

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial 

Hazard Ratios and Improvements in Median PFS are Unprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death by 76% vs. fulvestrant...

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 SYDNEY, July 28, 2025 (GLOBE NEWSWIRE) --...

Smith Profits Offers Shriners Children's Hospital the Opportunity to Transform Young Patients into #1 Best Selling Authors Through Patriotic Book Series

Smith Profits Offers Shriners Children's Hospital the Opportunity to Transform Young Patients into #1 Best Selling Authors Through Patriotic Book Series

WINTER GARDEN, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Smith Profits, the Winter Garden, Florida-based business consulting and publishing company, announced a groundbreaking opportunity for Shriners Children's Hospital to launch "WHAT I LOVE ABOUT...

New Book Blends Medical Expertise, Humor, and Philosophy to Tackle Kidney Stones

New Book Blends Medical Expertise, Humor, and Philosophy to Tackle Kidney Stones

Dr. Carmin M. Kalorin's New Book Offers a Guide to Surviving "Those Dirty, Rotten Little Bastards" with Wit and Wisdom NC, UNITED STATES, July 28, 2025 /⁨EINPresswire.com⁩/ -- For millions of people worldwide, kidney stones rank among life's most...

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...

Genetic Testing Market to Soar to $54.2B by 2033, Driven by Personalized Medicine and Tech Innovation

Genetic Testing Market to Soar to $54.2B by 2033, Driven by Personalized Medicine and Tech Innovation

With a CAGR of 15.4%, the genetic testing market is fueled by rising disease prevalence, DTC demand, and major M&A activity in 2025. LOS ANGELES, CA, UNITED STATES, July 28, 2025 /⁨EINPresswire.com⁩/ -- The global genetic testing market size was...

CVRx Reports Second Quarter 2025 Financial and Operating Results

CVRx Reports Second Quarter 2025 Financial and Operating Results

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with...

Smith Profits and Junior Patriots Offer St. Jude Children's Research Hospital the Opportunity to Help Patients Become #1 Best Selling Authors

Smith Profits and Junior Patriots Offer St. Jude Children's Research Hospital the Opportunity to Help Patients Become #1 Best Selling Authors

WINTER GARDEN, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Smith Profits, the Winter Garden-based business consulting and publishing firm, announces a groundbreaking corporate social responsibility initiative to offer St. Jude Children's Research...

Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients

Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients

Optim.AI™ accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 27, 2025 /⁨EINPresswire.com⁩/ -- A prospective clinical study published in JCO Precision Oncology, a...

Sounding the Alarm on Health Care Cuts

Sounding the Alarm on Health Care Cuts

Earlier today, Governor Kathy Hochul joined elected and community leaders in Western New York to sound the alarm on Washington Republicans’ devastating agenda, including the recently enacted “Big Ugly Bill” that rips away health care coverage from...

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to...

Medical Alert Systems Sector Expected to Grow 10.9% Annually to $20.95 Billion by 2030, North America Leads

Medical Alert Systems Sector Expected to Grow 10.9% Annually to $20.95 Billion by 2030, North America Leads

Medical alert systems market was valued at $6.47 billion in 2020, is projected to reach $20.95 billion by 2030, registering a CAGR of 10.9% from 2021 to 2030. WILMINGTON, NEW CASTLE, DE, UNITED STATES, July 23, 2025 /⁨EINPresswire.com⁩/ --...

Proteomics Market Booming with Biomarker Discovery and Precision Medicine Advancements, 2032 | Coherent Market Insights

Proteomics Market Booming with Biomarker Discovery and Precision Medicine Advancements, 2032 | Coherent Market Insights

BURLINGAME, CA, UNITED STATES, July 28, 2025 /⁨EINPresswire.com⁩/ -- The latest Proteomics Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected...

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive...

Medical Silicone Molding Market is Forecasted to Reach US$5.9 Billion in 2030, Says Stratview Research

Medical Silicone Molding Market is Forecasted to Reach US$5.9 Billion in 2030, Says Stratview Research

Detroit, July 23, 2025 (GLOBE NEWSWIRE) -- The global medical silicone molding market size was valued at US$3.8 billion in 2023 and is projected to reach US$5.9 billion by 2030, witnessing a market growth CAGR of 6.3% from 2024 to 2030, according...

Why XentaFlex Is Emerging as 2025’s Most Affordable, Simplest, and Most Effective Joint Pain Solution

Why XentaFlex Is Emerging as 2025’s Most Affordable, Simplest, and Most Effective Joint Pain Solution

Salt Lake City, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A growing number of Americans are questioning the same outdated joint pain “remedies” they’ve relied on for years in 2025. From glucosamine pills to endless collagen powders, solutions once trusted...

OwlTing Introduces OwlPay Stablecoin Checkout for Global Businesses

OwlTing Introduces OwlPay Stablecoin Checkout for Global Businesses

ARLINGTON, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OwlTing Group (the “Company”), a global blockchain fintech company, today announced the launch of OwlPay Stablecoin Checkout, a new API-embedded stablecoin acquiring1 function set to go live this...

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions